Organon & Co. (OGN) income statement
OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 8/302% below fair value
$13.89−0.02 (-0.14%)
Close on Nov 20, 2026Market cap $3.65BP/E 18.0Yield 2.45%
Organon & Co. financial ratios
See a number that looks wrong?